Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Blood (2019) 134 (Supplement_1): 245.

https://doi.org/10.1182/blood-2019-129624

Published: 2019

Journal Articles

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Ran Reshef, MDMSc, David B. Miklos, MD PhD, John M. Timmerman, MD, Caron A. Jacobson, MD MMSc, Nabila N. Bennani, MD, John M. Rossi, MS, Marika Sherman, MS, Lianqing Zheng, PhD, Jennifer Sun, MS, Gabrielle Palluconi, BS, Jenny J. Kim, MD MS, Michael D. Jain, MD PhD

Blood (2019) 134 (Supplement_1): 4084.

https://doi.org/10.1182/blood-2019-123772

Published: 2019

Journal Articles

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy

Caron A. Jacobson, MD, Alex F. Herrera, MD, Lihua E Budde, MD PhD, Daniel J. DeAngelo, MD, Christopher Heery, MD, Anthony Stein, MD, Michael D. Jain, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 4107.

https://doi.org/10.1182/blood-2019-128203

Published: 2019

Journal Articles

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

Michael D. Jain, MD PhD, Rawan Faramand, MD, Verena Staedtke, MD PhD, Renyuan Bai, MBBS, Sae Bom Lee, Hiroshi Kotani, MD PhD, Kayla Reid, Kristen Spitler, Julio Chavez, Bijal Shah, MD, Christina A Bachmeier, PharmD, Marian Dam, ARNP, Brigett Brandjes, PA, Ricardo J Gonzalez, MD, John E Mullinax, MD PhD, Xuefeng Wang, PhD, Mohammad Hussaini, MD, Frederick L. Locke, MD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 4105.

https://doi.org/10.1182/blood-2019-127305

Published: 2019

Journal Articles

Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma

Michael D. Jain, MD PhD, Hua Zhao, Reginald Atkins, Meghan A Menges, Crystal R Pope, Rawan Faramand, MD, Sae Bom Lee, Justin C. Boucher, PhD, Hiroshi Kotani, MD PhD, Christina A Bachmeier, PharmD, Julio Chavez, Bijal Shah, MD, Mohammad Hussaini, MD, Ricardo J Gonzalez, MD, John E Mullinax, MD PhD, Marco L. Davila, MD PhD, Frederick L. Locke, MD

Blood (2019) 134 (Supplement_1): 2885.

https://doi.org/10.1182/blood-2019-131041

Published: 2019

Journal Articles

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

Blood (2019) 134 (Supplement_1): 763.

https://doi.org/10.1182/blood-2019-129097

Published: 2019

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Anca Prica, MD, Ryan D. Morin, PhD, Vishal Kukreti, MD, Robert Kridel, MDMPH,PhD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, Miguel Alcaide, Rashmi S. Goswami, MD PhD, Jan Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, MBChB, PhD, John Kuruvilla, MD

Blood (2019) 134 (Supplement_1): 2027.

https://doi.org/10.1182/blood-2019-131818

Published: 2019

Journal Articles

Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Blood (2019) 134 (Supplement_1): 1583.

https://doi.org/10.1182/blood-2019-131168

Published: 2019

Journal Articles

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

Hamza Hashmi, MD, Alicia Darwin, Christina A Bachmeier, PharmD, Julio Chavez, Bijal Shah, MD, Javier Pinilla Ibarz, MD PhD, Taiga Nishihori, MD, Farhad Khimani, MD, Aleksandr Lazaryan, MDPhDMPH, Hien D. Liu, MD, Marco L. Davila, MD PhD, Frederick L. Locke, MD, Michael D. Jain, MD PhD

Blood (2019) 134 (Supplement_1): 1612.

https://doi.org/10.1182/blood-2019-126148

Published: 2019

Journal Articles

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Sepideh Mokhtari, MD, Justin M Asquith, MD, Christina A Bachmeier, PharmD, Michael D. Jain, MD PhD, Peter Forsyth, MD, Frederick L. Locke, MD, Youngchul Kim, PhD, Aleksandr Lazaryan, MD PhD MPH

Blood (2019) 134 (Supplement_1): 5627.

https://doi.org/10.1182/blood-2019-122343

Published: 2019

Journal Articles

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Blood (2019) 134 (Supplement_1): 921.

https://doi.org/10.1182/blood-2019-127399

Published: 2019

Journal Articles

Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel

Michael D. Jain, MD PhD, Julio C. Chavez, MD, Bijal D. Shah, MD, Farhad Khimani, MBBS, Aleksandr Lazaryan, MD PhD MPH, Marco L. Davila, MD PhD, Hien D. Liu, MD, Aaron D Falchook, MD, Timothy Robinson, MD, Sungjune Kim, MD PhD, Frederick L. Locke, MD

Blood (2018) 132 (Supplement 1): 4220.

https://doi.org/10.1182/blood-2018-99-117133

Published: 2018

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Ryan D. Morin, PhD BSc, MSc, Anca Prica, MD, Vishal Kukreti, MD, Robert Kridel, PhD MD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, BSc, Miguel Alcaide, PhD, Rashmi S. Goswami, BSc, MD PhD FRCPC, Jan M.A. Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, PhD MD, FRACP, FRCPA, John Kuruvilla, MD

Blood (2018) 132 (Supplement 1): 4610.

https://doi.org/10.1182/blood-2018-99-117333

Published: 2018

Journal Articles

Patient-Reported and Neurocognitive Outcomes in Patients Treated with Axicabtagene Ciloleucel

Heather S.L. Jim, PhD, Aasha I. Hoogland, PhD, Aaron Collier, Margaret Booth-Jones, PhD, Michael D. Jain, MD PhD, Frederick L. Locke, MD

Blood (2018) 132 (Supplement 1): 2289.

https://doi.org/10.1182/blood-2018-99-111711

Published: 2018

NARROW

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Patient-Reported and Neurocognitive Outcomes in Patients Treated with Axicabtagene Ciloleucel

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only